Active surveillance of prostate cancer: MRI and beyond
- 28.03.2024
- Editorial
Erschienen in:
- Verfasst von
- Rossano Girometti
- Francesco Giganti
- Erschienen in
- European Radiology | Ausgabe 10/2024
Auszug
Active surveillance (AS) is a management strategy aiming at avoiding overtreatment of a newly diagnosed low-risk prostate cancer until there is evidence of disease progression at repeat testing [1]. Although the definition of low-risk cancer varies according to different institutions and guidelines, and more than one-third of patients will be reclassified as higher risk during AS, this conservative approach translates into a cancer-specific survival up to 100% [1] and should be offered to patients with a life expectancy of at least 10 years according to the European guidelines [2]. Based on these premises, it is a matter of debate whether AS should be extended to favourable intermediate-risk cancers as currently supported by the UK National Institute for Health and care Excellence (NICE) or the US National Comprehensive Cancer Network (NCCN) guidelines [1]. …
Anzeige
- Titel
- Active surveillance of prostate cancer: MRI and beyond
- Verfasst von
-
Rossano Girometti
Francesco Giganti
- Publikationsdatum
- 28.03.2024
- Verlag
- Springer Berlin Heidelberg
- Erschienen in
-
European Radiology / Ausgabe 10/2024
Print ISSN: 0938-7994
Elektronische ISSN: 1432-1084 - DOI
- https://doi.org/10.1007/s00330-024-10717-4
Dieser Inhalt ist nur sichtbar, wenn du eingeloggt bist und die entsprechende Berechtigung hast.
